Global Enterovirus Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Enterovirus Vaccine Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Enterovirus is a genus of positive-sense single-stranded RNA viruses associated with several human and mammalian diseases. On the basis of their pathogenesis in humans and animals, the enteroviruses were originally classified into four groups, polioviruses, Coxsackie A viruses (CA), Coxsackie B viruses (CB), and echoviruses, but it was quickly realized that there were significant overlaps in the biological properties of viruses in the different groups. Enteroviruses isolated more recently are named with a system of consecutive numbers: EV-D68, EV-B69, EV-D70, EV-A71, etc., where genotyping is based on the VP1 capsid region.

Market Overview:

The latest research study on the global Enterovirus Vaccine market finds that the global Enterovirus Vaccine market reached a value of USD 2059.52 million in 2022. It’s expected that the market will achieve USD 3286.39 million by 2028, exhibiting a CAGR of 8.1% during the forecast period.

Enteroviruses affect millions of people worldwide each year and are usually found in the respiratory secretions (e.g., saliva, sputum, or nasal mucus) and feces of infected individuals. Enteroviruses are classified virologically as enteroviruses in the small ribonucleic acid virus family. Historically, polio was the most severe disease caused by enteroviruses (i.e., polioviruses). Poliovirus, coxsackievirus and echovirus are transmitted by the fecal-oral route. Infection can cause a variety of symptoms including: mild respiratory illness (common cold), hand, foot, and mouth disease, acute hemorrhagic conjunctivitis, aseptic meningitis, myocarditis, severe neonatal sepsis-like illness, acute flaccid paralysis, and associated acute flaccid myelitis.EV71 is the most recent virus found in the enterovirus group. It is highly infectious and pathogenic, with particular neurological complications.

The incidence of human hand-foot-mouth disease (HFMD) and the infection rate of enteroviruses have driven the demand for enterovirus vaccines and boosted the industry. Human hand-foot-and-mouth disease (HFMD) caused several large outbreaks across the Asian-Pacific region, and it represents a global public health issue. Several viruses were identified as the primary HFMD-related pathogens, and this list includes enterovirus A71 (EV-A71), coxsackievirus A16 (CV-A16), CV-A6 and CV-A10, which all belong to the genus Enterovirus within the Picornaviridae family. HFMD frequently occurs in children under five years old, and it is generally characterized by vesicular exanthema with self-limitation.

Hand, foot, and mouth disease (HFMD) recently emerged as a global public threat. The licensure of inactivated enterovirus A71 (EV-A71) vaccine was the first step in using a vaccine to control HFMD. New challenges arise from changes in the pathogen spectrum while vaccines directed against other common serotypes are in the preclinical stage. The mission of a broad-spectrum prevention strategy clearly favors multivalent vaccines. The development of multivalent vaccines was attempted via the simple combination of potent monovalent vaccines or the construction of chimeric vaccines comprised of epitopes derived from different virus serotypes.

Market entrance approvals and applications in other countries with significant targeted populations of babies and children face technological and legislative obstacles. Vaccine availability, the possibility of introducing the enterovirus vaccination into EPI, and the harmonization of vaccine standards are the hurdles. As a result, international collaboration is critical for controlling the spread of the enterovirus vaccination in underdeveloped countries. WHO should take the lead in developing enterovirus vaccine quality control and assessment standards. The world still has a long way to go before the cost-effective enterovirus vaccine is widely available.

Region Overview:

In 2021, the share of the Enterovirus Vaccine market in Asia-Pacific stood at 57.50%.

Company Overview:

Sanofi Pasteur

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.

Chinese Academy of Medical Sciences

China Academy of Chinese Medical Sciences was founded in 1955. It is a comprehensive Chinese medicine research institution directly under the State Administration of Traditional Chinese Medicine, integrating scientific research, medical treatment and teaching. It takes the scientific research of Chinese medicine as its central task.

Sanofi Pasteur is one of the major players operating in the Enterovirus Vaccine market, holding a share of 36.59% in 2022.

Segmentation Overview:

Among different product types, Human Enterovirus 71 segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Hospital segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Enterovirus Vaccine market covered in Chapter 3:

GSK
Chinese Academy of Medical Sciences
Sanofi Pasteur
Serum Institute
Sinovac Biotech

In Chapter 4 and Chapter 14.2, on the basis of types, the Enterovirus Vaccine market from 2018 to 2029 is primarily split into:

Human Enterovirus 71
Polioviruses

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Enterovirus Vaccine market from 2018 to 2029 covers:

Hospital
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)